"Oxazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered heterocycles containing an oxygen and a nitrogen.
| Descriptor ID |
D010078
|
| MeSH Number(s) |
D03.383.533
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oxazines".
Below are MeSH descriptors whose meaning is more specific than "Oxazines".
This graph shows the total number of publications written about "Oxazines" by people in this website by year, and whether "Oxazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 5 | 5 | 10 |
| 2022 | 0 | 7 | 7 |
| 2023 | 1 | 1 | 2 |
| 2024 | 6 | 3 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazines" by people in Profiles.
-
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378.
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.
-
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. J Int AIDS Soc. 2024 Jul; 27(7):e26268.
-
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. Clin Infect Dis. 2024 Jun 14; 78(6):1617-1628.
-
Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426.
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
-
Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024 Jul; 25(7):826-839.
-
Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
-
Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi's National HIV Treatment Program. Viruses. 2023 12 23; 16(1).